Tezepelumab 210mg/1.91ml solution for injection pre-filled disposable devices
NHS hospitals in England used £93,330,839 of indicative cost of Tezepelumab 210mg/1.91ml solution for injection pre-filled disposable devices in the 12 months to April 2026, about 0.4% of all hospital medicines spend. That is up 111.5% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Tezepelumab 210mg/1.91ml solution for injection pre-filled disposable devices: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Tezepelumab 210mg/1.91ml solution for injection pre-filled disposable devices most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Guy's & St Thomas' Nhs Foundation Trust | £20,063,304 |
| Manchester University Nhs Ft | £6,733,595 |
| University Hospital Southampton Nhs Ft | £4,543,880 |
| Aintree University Hospital Nhs Ft | £4,149,200 |
| Lancashire T/Ing Hsp Nhs Foundation Trus | £4,142,875 |
| University Hpls Of Leicester Nhs Trust | £3,190,330 |
| Barts Health Nhs Trust | £3,063,830 |
| Oxford University Hospitals Nhs Ft | £2,887,995 |
| Cambridge Univ Hosp Nhs Foundation Trust | £2,780,470 |
| Univ Hpl B/Ham Nhs Foundation Trust | £2,657,765 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.